AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
ESE

ESCO Technologies Inc. Common Stock (ESE) fair value

Technology · Scientific & Technical Instruments · NYSE · United States
$232.10-0.38%
Market cap $6.0BNext earnings 2026-11-19Updated Oct 20, 2026
Add earnings to calendarGoogle
Our verdict
Trades 34% above our fair value
Price
$232.10
Model fair valueConfidence: good
$173
Model range
$125 to $252
Fair value $173
Price $232
3 models fit ESCO Technologies Inc. Common Stock and they disagree: 0 of 3 land within 15% of the average.
Two or more of our models back this value.
Premium(i)
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
ACCE opinionESCO Technologies Inc. Common Stock (ESE)
Fair value (3 models)
$173
ACCE price target
$260
Rating
Overvalued
Horizon
12 months
Fair value published on 20 Oct 2026, 14:06 CEST; previously $145 since 15 Oct 2026, 00:00 CEST.
ACCE price target published on 10 Oct 2026, 00:00 CEST.
Rating published on 20 Oct 2026, 14:06 CEST.
Price used: $232 at the close on 23 Oct 2026, 22:00 CEST.
Models: P/E comparison, EV/EBITDA comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
34.3% above
-25.5% to fair value
ACCE score
53
out of 100
Analysts
100% buy
4 covering
P/E
43.1x
forward 25.2x
1-year return
+5.9%
Dividend yield
0.14%

ESCO Technologies Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

ESCO Technologies makes filtration and test-and-measurement products, including utility-grade meters and testing systems sold through its Utility Solutions and Test segments, along with aerospace and defense components. The structural case rests on a mix of regulated utility demand and specialty instruments that are hard to displace once specified into a customer's process. Revenue growth of 14.4% is well ahead of most of the instrumentation peer set, and the forward P/E of 25.4 sits far below the trailing 46.9, which implies the market expects earnings to catch up with the top line. The gap between a 42.0% gross margin and a 14.8% operating margin, together with a 9.5% ROE, means the business is converting sales into profit less efficiently than the headline growth suggests, so margin trajectory is the first thing to check. The name carries a score of 56/100 and no index membership, so it sits outside the screens that usually force attention, which makes it worth a deeper look mainly to test whether the forward earnings recovery is real.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
  • moderate
    Valuation stretched vs model
    Stock trades 34.3% above the model fair value of $172.87, with P/E at 46.6 against a forward P/E of 25.4. Expectations are demanding.
  • moderate
    Score down sharply in 90 days
    ACCE score fell 15 points from 70 to 55 over 90 days, led by a weak Valuation sub-score of 38 and Momentum of 39.
  • moderate
    Insider selling, no buying
    Last 10 disclosed insider trades total $2.89M in sales and $0.00M in buys, a one-directional signal from insiders holding 20.1% of shares.

AI research notes

AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-10-20 · prices to Oct 23, 2026
Why it could do well
  • Revenue grew 14.4% over the past year, well ahead of its 8.4% average annual pace over five years.
  • Free cash flow over the last twelve months reached $190M, and debt is light at 0.15 times equity.
Why it could disappoint
  • The shares trade 34.3% above the model fair value of $172.87, and three of four valuation models sit there.
  • At 46.6 times trailing earnings and 25.4 times forward, the stock is priced for growth that the cash flow yield of 2.9% does not support.
  • Net margin of 24.4% runs well above operating margin, which may reflect one-off gains rather than repeatable profit.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 19, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where ESE's valuation models land
Price
$232.10
Model fair value
$173
Model range
$125 to $252
Fair value $173
Price $232
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish100% buy · 4 covering analysts
● Strong buy 2● Buy 2● Hold 0● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
3 buys · 1 sell
Since Aug 19, 2026, 1 member
Average delay
10 days
From trade to public filing
Full trade list on ProDo politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
-6.8%
1 month
-12.8%
3 months
-29.2%
6 months
-27.4%
YTD
+18.8%
1 year
+5.9%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
20 Oct 2026, 14:06 CESTFair value$173$145$251
20 Oct 2026, 14:06 CESTRatingOvervaluedfirst publication$251
15 Oct 2026, 00:00 CESTFair value$145$148$260
11 Oct 2026, 00:00 CESTFair value$148$152$258
10 Oct 2026, 00:00 CESTACCE price target$260first publication$254
6 Oct 2026, 00:00 CESTFair value$152$155$275
4 Oct 2026, 00:00 CESTFair value$155$146$275
19 Sept 2026, 00:00 CESTFair value$146$143$260
16 Sept 2026, 00:00 CESTFair value$143$145$263
11 Sept 2026, 00:00 CESTFair value$145$148$271

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full ESE page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth68Value38Quality73Momentum32Total53
Valuation
Trailing P/E
43.1x
Forward P/E
25.2x
PEG
1.85
P/B
4.17x
EV / Revenue
5.3x
Book value/sh
$62.42
Enterprise value
$7.0B
Profitability
ROE
9.5%
FCF yield
2.96%
ROIC
13.9%
Health and risk
Debt / equity
0.15
Dividend yield
0.14%
Beta
1.05

Price

+4.9% · 1Y

Ask anything about ESE

Answered from ESCO Technologies Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 67% of peers
low 21.9x43.1xhigh 89.1x
ROEbetter than 33% of peers
low 3%10%high 31%
Div yieldbetter than 17% of peers
low 0.0%0.1%high 1.6%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
ESE ESCO Technologies Inc. Common Stock$232.10$17334% above43.1x9.5%7353
6856.T HORIBA, Ltd.¥22380.00--21.9x12.7%7672
ST Sensata Technologies Holding plc Ordinary Shares$40.70$2469% above67.3x3.1%5059
NOVT Novanta Inc. Common Stock$136.66$49179% above89.1x5.1%6460
CDA.AX Codan LimitedA$56.53A$3278% above58.7x30.9%9678
RSW.L Renishaw plc£53.60£3460% above31.5x12.5%8376
IFCN.SW INFICON Holding AGCHF 166.60CHF 76120% above51.9x24.5%8473

Sector report card

Where ESE ranks against its sector peers on each metric.

Computing percentiles…
  • GlobeNewswire•Oct 1, 2026
    ESCO Completes Acquisition of Megger Group Limited
  • GlobeNewswire•Jun 24, 2026
    Global Laboratory Equipment Services Market Size/Share Worth USD 62.83 Billion by 2035 at a 8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
40 filings
October 2026
Oct 16
Form 4Insider transactionPeriod 2026-10-15
View on SEC →
Oct 16
Form 4Insider transactionPeriod 2026-10-15
View on SEC →
Oct 16
Form 4Insider transactionPeriod 2026-10-15
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR